Apolipoprotein E polymorphism in omani dyslipidemic patients with and without coronary artery disease

Said Ali S Al-Yahyaee, Shyam Sundar Ganguly, Mohammed Nasser Al-Kindi, Ali Ihassan Al-Bahrani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Apolipoprotein E (APOE) polymorphism is a predictor of interindividual variability in plasma levels of lipids and lipoproteins and a predictor of risk of coronary artery disease (CAD). We studied the relationship between APOE polymorphism and lipid profiles and risk of CAD in Omani dyslipidemic patients. This retrospective study included 244 dyslipidemic patients, of whom 67 had CAD. Fasting blood glucose, lipids, and plasma lipoprotein levels were measured using standard methods, and APOE genotypes were detected by PCR-RFLP. The dyslipidemic patients had the following APOE allele frequencies: APOE*2, 0.030; APOE*3, 0.894; and APOE*4, 0.076. APOE allele frequencies between patients with and without CAD showed no significant differences. Compared to APOE*3/*3 homozygotes, APOE*4 allele patients had higher mean levels of low-density lipoprotein (LDL) cholesterol (p = 0.014), apoB (p = 0.031), lower mean levels of apoA1 (p = 0.043), and a trend of higher mean level of total cholesterol (p = 0.084). Thirty-one percent of patients with CAD had the APOE*4 allele compared to 26% with the APOE*3 allele, but this difference was not significant. Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia. In conclusion, among dyslipidemic patients, carriers of APOE*4 compared to homozygous carriers of APOE*3 had significantly higher levels of LDL cholesterol and apoB, but no relationship with CAD was found.

Original languageEnglish
Pages (from-to)93-102
Number of pages10
JournalHuman Biology
Volume79
Issue number1
Publication statusPublished - Feb 2007

Fingerprint

apolipoprotein E
Apolipoproteins E
Apolipoprotein E3
Coronary Artery Disease
Apolipoprotein E4
polymorphism
genetic polymorphism
allele
Alleles
lipid
Homozygote
Apolipoproteins B
Dyslipidemias
Lipids
Gene Frequency
LDL Cholesterol
Lipoproteins
plasma
Apolipoprotein E2
fasting

Keywords

  • Apolipoprotein E (APOE) polymorphism
  • Coronary artery disease
  • Dyslipidemia
  • Omani population

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Genetics
  • Genetics(clinical)
  • Ecology, Evolution, Behavior and Systematics

Cite this

Apolipoprotein E polymorphism in omani dyslipidemic patients with and without coronary artery disease. / Al-Yahyaee, Said Ali S; Ganguly, Shyam Sundar; Al-Kindi, Mohammed Nasser; Al-Bahrani, Ali Ihassan.

In: Human Biology, Vol. 79, No. 1, 02.2007, p. 93-102.

Research output: Contribution to journalArticle

@article{9657b38d2eca47daa912482496601421,
title = "Apolipoprotein E polymorphism in omani dyslipidemic patients with and without coronary artery disease",
abstract = "Apolipoprotein E (APOE) polymorphism is a predictor of interindividual variability in plasma levels of lipids and lipoproteins and a predictor of risk of coronary artery disease (CAD). We studied the relationship between APOE polymorphism and lipid profiles and risk of CAD in Omani dyslipidemic patients. This retrospective study included 244 dyslipidemic patients, of whom 67 had CAD. Fasting blood glucose, lipids, and plasma lipoprotein levels were measured using standard methods, and APOE genotypes were detected by PCR-RFLP. The dyslipidemic patients had the following APOE allele frequencies: APOE*2, 0.030; APOE*3, 0.894; and APOE*4, 0.076. APOE allele frequencies between patients with and without CAD showed no significant differences. Compared to APOE*3/*3 homozygotes, APOE*4 allele patients had higher mean levels of low-density lipoprotein (LDL) cholesterol (p = 0.014), apoB (p = 0.031), lower mean levels of apoA1 (p = 0.043), and a trend of higher mean level of total cholesterol (p = 0.084). Thirty-one percent of patients with CAD had the APOE*4 allele compared to 26{\%} with the APOE*3 allele, but this difference was not significant. Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia. In conclusion, among dyslipidemic patients, carriers of APOE*4 compared to homozygous carriers of APOE*3 had significantly higher levels of LDL cholesterol and apoB, but no relationship with CAD was found.",
keywords = "Apolipoprotein E (APOE) polymorphism, Coronary artery disease, Dyslipidemia, Omani population",
author = "Al-Yahyaee, {Said Ali S} and Ganguly, {Shyam Sundar} and Al-Kindi, {Mohammed Nasser} and Al-Bahrani, {Ali Ihassan}",
year = "2007",
month = "2",
language = "English",
volume = "79",
pages = "93--102",
journal = "Human Biology",
issn = "0018-7143",
publisher = "Wayne State University Press",
number = "1",

}

TY - JOUR

T1 - Apolipoprotein E polymorphism in omani dyslipidemic patients with and without coronary artery disease

AU - Al-Yahyaee, Said Ali S

AU - Ganguly, Shyam Sundar

AU - Al-Kindi, Mohammed Nasser

AU - Al-Bahrani, Ali Ihassan

PY - 2007/2

Y1 - 2007/2

N2 - Apolipoprotein E (APOE) polymorphism is a predictor of interindividual variability in plasma levels of lipids and lipoproteins and a predictor of risk of coronary artery disease (CAD). We studied the relationship between APOE polymorphism and lipid profiles and risk of CAD in Omani dyslipidemic patients. This retrospective study included 244 dyslipidemic patients, of whom 67 had CAD. Fasting blood glucose, lipids, and plasma lipoprotein levels were measured using standard methods, and APOE genotypes were detected by PCR-RFLP. The dyslipidemic patients had the following APOE allele frequencies: APOE*2, 0.030; APOE*3, 0.894; and APOE*4, 0.076. APOE allele frequencies between patients with and without CAD showed no significant differences. Compared to APOE*3/*3 homozygotes, APOE*4 allele patients had higher mean levels of low-density lipoprotein (LDL) cholesterol (p = 0.014), apoB (p = 0.031), lower mean levels of apoA1 (p = 0.043), and a trend of higher mean level of total cholesterol (p = 0.084). Thirty-one percent of patients with CAD had the APOE*4 allele compared to 26% with the APOE*3 allele, but this difference was not significant. Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia. In conclusion, among dyslipidemic patients, carriers of APOE*4 compared to homozygous carriers of APOE*3 had significantly higher levels of LDL cholesterol and apoB, but no relationship with CAD was found.

AB - Apolipoprotein E (APOE) polymorphism is a predictor of interindividual variability in plasma levels of lipids and lipoproteins and a predictor of risk of coronary artery disease (CAD). We studied the relationship between APOE polymorphism and lipid profiles and risk of CAD in Omani dyslipidemic patients. This retrospective study included 244 dyslipidemic patients, of whom 67 had CAD. Fasting blood glucose, lipids, and plasma lipoprotein levels were measured using standard methods, and APOE genotypes were detected by PCR-RFLP. The dyslipidemic patients had the following APOE allele frequencies: APOE*2, 0.030; APOE*3, 0.894; and APOE*4, 0.076. APOE allele frequencies between patients with and without CAD showed no significant differences. Compared to APOE*3/*3 homozygotes, APOE*4 allele patients had higher mean levels of low-density lipoprotein (LDL) cholesterol (p = 0.014), apoB (p = 0.031), lower mean levels of apoA1 (p = 0.043), and a trend of higher mean level of total cholesterol (p = 0.084). Thirty-one percent of patients with CAD had the APOE*4 allele compared to 26% with the APOE*3 allele, but this difference was not significant. Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia. In conclusion, among dyslipidemic patients, carriers of APOE*4 compared to homozygous carriers of APOE*3 had significantly higher levels of LDL cholesterol and apoB, but no relationship with CAD was found.

KW - Apolipoprotein E (APOE) polymorphism

KW - Coronary artery disease

KW - Dyslipidemia

KW - Omani population

UR - http://www.scopus.com/inward/record.url?scp=35548992815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548992815&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 93

EP - 102

JO - Human Biology

JF - Human Biology

SN - 0018-7143

IS - 1

ER -